Neuroendocrine Tumour (VMT-𝛼-NET) programs
UPDATE 10 SEP 2021.Viewpoint Molecular Targeting (TM) Receives FDA Clearance of Investigational New Drug Application for Phase 1 Imaging Study for VMT-a-NET for Neuroendocrine Tumors3 years ago, I wrote about an emerging type of peptide receptor radionuclide therapy (PRRT) suggesting it could be next generation. That work continues. It was being labelled with the term "Targeted Alpha-emitter Therapy (TAT)" using "alpha particles". The current approved types of PRRT use beta particles so is a totally different method. You might be thinking what the differences are and how does it affect me? You can read more in my article PRRT – The Sequel? – Targeted Alpha-emitter Therapy (TAT).I also wrote about the term THERANOSTICS, a combo term for THERAPY and DIAGNOSTICS. In the same way that you have a theranostic pair…